Details checkedClinical trial listing onlyCheckedregistry

Sunnybrook sodium thiosulfate plus mannitol cisplatin otoprotection study

Also known as: Sodium Thiosulfate + Mannitol, STS + mannitol, NCT05129748, 1818

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Active

Target Gene

—

Route / Mode

Intravenous infusion

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Canada

Population

adult, cisplatin-ototoxicity, otoprotection, cancer

Trial IDs

Mechanism

Intravenous sodium thiosulfate plus mannitol administered 4-8 hours after cisplatin chemotherapy to reduce adult cisplatin-induced ototoxic hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss Cisplatin-Induced Hearing Loss Ototoxicity

Notes

Corrected from a hospital-as-company row. ClinicalTrials.gov lists Sunnybrook Health Sciences Centre as the non-industry lead sponsor of this active randomized Phase 2 cisplatin otoprotection trial.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT05129748, 1818

Open

Key Events

2021-11-22

Sunnybrook sodium thiosulfate plus mannitol otoprotection trial first posted

2023-04-14

ClinicalTrials.gov update lists the study as recruiting

Clinical Trials (1)